MX2023004017A - Método para tratar la enfermedad de crohn con anticuerpo anti-il12/il23. - Google Patents

Método para tratar la enfermedad de crohn con anticuerpo anti-il12/il23.

Info

Publication number
MX2023004017A
MX2023004017A MX2023004017A MX2023004017A MX2023004017A MX 2023004017 A MX2023004017 A MX 2023004017A MX 2023004017 A MX2023004017 A MX 2023004017A MX 2023004017 A MX2023004017 A MX 2023004017A MX 2023004017 A MX2023004017 A MX 2023004017A
Authority
MX
Mexico
Prior art keywords
disease
antibody
crohn
treating crohn
dosing
Prior art date
Application number
MX2023004017A
Other languages
English (en)
Inventor
Frederic Lavie
Bars Manuela Le
Michael Plotnick
Sheldon Sloan
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2023004017A publication Critical patent/MX2023004017A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4727—Calcium binding proteins, e.g. calmodulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Métodos y composiciones para el tratamiento probado como seguro y efectivo de la enfermedad de Crohn, particularmente la enfermedad de Crohn activa de moderada a grave en pacientes, que comprenden dosis inicial intravenosa y dosis de mantenimiento subcutánea de un anticuerpo IL12/IL23p40 con intervalos de dosis de mantenimiento determinados mediante la evaluación de indicadores clínicos.
MX2023004017A 2020-10-09 2021-10-07 Método para tratar la enfermedad de crohn con anticuerpo anti-il12/il23. MX2023004017A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063089786P 2020-10-09 2020-10-09
US202163235188P 2021-08-20 2021-08-20
PCT/IB2021/059211 WO2022074603A1 (en) 2020-10-09 2021-10-07 Method for treating crohn's disease with anti-il12/il23 antibody

Publications (1)

Publication Number Publication Date
MX2023004017A true MX2023004017A (es) 2023-07-05

Family

ID=81078738

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004017A MX2023004017A (es) 2020-10-09 2021-10-07 Método para tratar la enfermedad de crohn con anticuerpo anti-il12/il23.

Country Status (10)

Country Link
US (1) US20220112282A1 (es)
EP (1) EP4225350A1 (es)
JP (1) JP2023544620A (es)
KR (1) KR20230084283A (es)
CN (1) CN116348491A (es)
AU (1) AU2021356282A1 (es)
CA (1) CA3198413A1 (es)
IL (1) IL301944A (es)
MX (1) MX2023004017A (es)
WO (1) WO2022074603A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111471655B (zh) * 2020-03-19 2023-07-07 湖州正熙医学检验实验室有限公司 抗人il12/23稳转细胞株及其构建方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200197517A1 (en) * 2018-12-18 2020-06-25 Janssen Biotech, Inc. Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody

Also Published As

Publication number Publication date
US20220112282A1 (en) 2022-04-14
CA3198413A1 (en) 2022-04-14
WO2022074603A1 (en) 2022-04-14
KR20230084283A (ko) 2023-06-12
IL301944A (en) 2023-06-01
EP4225350A1 (en) 2023-08-16
JP2023544620A (ja) 2023-10-24
AU2021356282A1 (en) 2023-06-15
CN116348491A (zh) 2023-06-27

Similar Documents

Publication Publication Date Title
MX2022015499A (es) Metodos para tratar la enfermedad de crohn y la colitis ulcerosa.
RS20080391A (en) Methods of treating inflammatory and autoimmune diseases with natalizumab
MX2009011540A (es) Tratamiento de desordenes de movimiento con el uso combinado de toxina botulinica y estimulacion del musculo.
MD3883606T3 (ro) Metodă sigură și eficientă de tratament al colitei ulcerative cu anticorpi anti-IL12/IL23
MX355611B (es) Formulaciones de anticuerpos monoclonales de alta concentracion.
EA201491460A1 (ru) ПРИМЕНЕНИЕ ЛАХИНИМОДА В ЛЕЧЕНИИ ПАЦИЕНТОВ С БОЛЕЗНЬЮ КРОНА, У КОТОРЫХ НЕ ЭФФЕКТИВНА ТЕРАПИЯ ПЕРВОЙ ЛИНИИ АНТИ-TNFα
AR109103A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
MX2022010483A (es) Metodos de tratamiento del complejo de esclerosis tuberosa con cannabidiol y everolimus.
JP2014516986A5 (es)
RU2012110324A (ru) Способы лечения хронического нейрогенного воспаления с помощью модифицированного клостридиального токсина
MX2023004017A (es) Método para tratar la enfermedad de crohn con anticuerpo anti-il12/il23.
MX2022013923A (es) Metodos para tratar la enfermedad de crohn con el anticuerpo especifico anti-il23.
NZ754328A (en) Marker for acid sphingomyelinase disorders and uses thereof
Hug Optimization of analgesia for piglet castration under isoflurane anaesthesia with parenteral butorphanol, meloxicam or intratesticular lidocaine
MX2021015228A (es) Metodos y composiciones para mejorar resultados de pacientes con cancer.
JP2013520447A5 (es)
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
CN108392743A (zh) 具有610-650nm波长的LED-红光在缓解腰肌劳损症状中的应用
MX2022001153A (es) Regimen de dosificacion y administracion para el tratamiento o prevencion de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab.
MX2014013380A (es) Usos de cxcl17, un nuevo marcador de quimiocinas de enfermedad pulmonar y gastrointestinal humana.
Suwansrinon et al. Is injecting a finger with rabies immunoglobulin dangerous?
MX2022009987A (es) Método seguro y efectivo para tratar la colitis ulcerosa con el anticuerpo anti-il-12/il23.
Orlova et al. THU0591 Comparative Efficacy of Two Exercises Programs in Patients with Early Rheumatoid Arthritis: 6-Month Randomized Controlled Trial
MX2022004581A (es) Método seguro y eficaz para tratar la colitis ulcerosa con el anticuerpo anti-il12/il23.
MX2022016174A (es) Composiciones y metodos para tratar un trastorno obsesivo-compulsivo.